High prevalence of type b beta-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced

The Journal of Antimicrobial Chemotherapy
Keiko HasegawaNationwide Surveillance for Bacterial Meningitis

Abstract

To study yearly changes in resistance and to identify ftsI mutations in beta-lactamase-non-producing ampicillin-resistant (BLNAR) and TEM-1 beta-lactamase-producing amoxicillin/clavulanic acid-resistant (BLPACR) isolates of Haemophilus influenzae from patients with meningitis. Between January 2000 and December 2004, we received 621 isolates of H. influenzae from 285 member institutions of the Nationwide Surveillance Study Group for Bacterial Meningitis. All isolates were analysed by PCR to identify resistance genes and tested for susceptibility to beta-lactams. The ftsI gene was sequenced in all BLNAR and BLPACR isolates. All but four isolates were of serotype b. The isolates could be divided into six classes, namely beta-lactamase-non-producing ampicillin-susceptible (25.0%), TEM-1 beta-lactamase-producing ampicillin-resistant (11.0%), beta-lactamase-non-producing low-level ampicillin-resistant with N526K or R517H substitution in the ftsI gene (30.4%), BLNAR with an S385T substitution together with either N526K or R517H substitution in ftsI (22.2%), BLPACR-I with either a N526K or R517H substitution in ftsI (9.5%) and BLPACR-II with an S385T substitution together with either a N526K or R517H substitution in ftsI (1.9%). The pr...Continue Reading

Citations

Mar 23, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T KastrinUNKNOWN Slovenian Meningitidis Study Group
Jun 23, 2009·Epidemiology and Infection·N ChibaUNKNOWN IPD Surveillance Study Group
Jan 15, 2013·The Journal of Antimicrobial Chemotherapy·Elizabeth A Witherden, Stephen G Tristram
Apr 13, 2007·Clinical Microbiology Reviews·Stephen TristramPeter C Appelbaum
Jul 9, 2010·Clinical Microbiology Reviews·Matthijs C BrouwerDiederik van de Beek
Feb 2, 2013·Clinical and Translational Medicine·Paul King
Feb 23, 2012·Fukushima Journal of Medical Science·Ayumi MatsumotoMitsuaki Hosoya
Oct 25, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M P Bajanca-LavadoUNKNOWN Portuguese Group for Study of Haemophilus influenzae invasive infection
Nov 23, 2006·International Journal of Pediatric Otorhinolaryngology·Dewan S BillalNoboru Yamanaka
Nov 8, 2013·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Tadashi HoshinoChie Fukasawa
Mar 17, 2011·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Hiroshi Sakata
Dec 18, 2012·Journal of Medical Microbiology·Michael E WatsonArnold L Smith
Sep 19, 2012·Expert Opinion on Pharmacotherapy·Seon Hee Shin, Kwang Sik Kim
Apr 28, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Naoko ChibaKimiko Ubukata
Mar 30, 2018·Journal of Medical Microbiology·Yoko AdachiSatoshi Iwata
May 23, 2018·Antimicrobial Agents and Chemotherapy·Kazuki KitaokaYoshichika Arakawa
Feb 21, 2008·The Tohoku Journal of Experimental Medicine·Chiharu KajiHiroshi Watanabe
Aug 14, 2009·Pediatrics International : Official Journal of the Japan Pediatric Society·Kiyoko TomochikaSusumu Furukawa
May 8, 2009·Pediatrics International : Official Journal of the Japan Pediatric Society·Misao TakanoTatsuo Yamamoto
May 17, 2011·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Niels Nørskov-LauritsenKurt Fuursted
Dec 5, 2012·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Satoshi Kamei
May 21, 2019·The Pediatric Infectious Disease Journal·Jesus G VallejoSheldon L Kaplan
Feb 23, 2010·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Keisuke SunakawaYoshitake Sato
Dec 8, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshiko UchidaTakashi Fukaya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.